Table 1.
Baseline characteristics of patients aged ≥ 65 years (n = 108)
| Category | n or mean ± SD |
|---|---|
| Gender (Male/Female) | 54/54 |
| Age | 68.2 ± 2.8 |
| Body Weight (kg) | 58.4 ± 9.5 |
| Body mass index (kg/m2) | 23.3 ± 3.0 |
| History of interferon therapy (yes/no) | 40/68 |
| History of diabetes mellitus (yes/no) | 19/89 |
| History of hypertension (yes/no) | 47/61 |
| White blood cells (/mm3) | 4909 ± 1332 |
| Red blood cells (× 104/mm3) | 436.1 ± 39.8 |
| Hemoglobin (g/dL) | 13.8 ± 1.2 |
| Platelets (× 104/mm3) | 15.3 ± 3.9 |
| AST (IU/L) | 65.2 ± 37.3 |
| ALT (IU/L) | 76.0 ± 65.5 |
| AFP (ng/ml) | 15.7 ± 31.4 |
| Histology (METAVIR) Fibrosis (1/2/3/4) | 22/41/37/8 |
| Histology (METAVIR) Activity (1/2/3) | 30/51/27 |
| HCV genotype (1/2) | 86/22 |
| Serum HCV RNA (KIU/ml) | 1650 ± 1521 |
| Peg-IFN dose (g/kg/week) | 1.22 ± 0.32 |
| Total Peg-IFN dose > 80% (yes/no) | 63/45 |
| Daily ribavirin dose (mg/kg) | 9.58 ± 2.93 |
| Total ribavirin dose > 80% (yes/no) | 63/45 |
Data are shown as absolute values or mean ± standard deviation. AST aspartate aminotransferase; ALT alanine aminotransferase; AFP alpha-fetoprotein; HCV hepatitis C virus; Peg-IFN pegylated interferon